Adverse events (serious adverse reaction and adverse reaction) · children and adults with CF
Probiotics showed no clear difference in adverse events (serious adverse reaction and adverse reaction) compared with placebo (low certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · patients with osteoarthritis
1 finding from 1 review
Number of participants experiencing any serious adverse events · patients with osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants experiencing any serious adverse events · patients with osteoarthritis
It is very uncertain whether tramadol alone changes number of participants experiencing any serious adverse events compared with NSAIDs (very low certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · patients with osteoarthritis
It is very uncertain whether tramadol alone changes number of participants experiencing any serious adverse events compared with other opioids (very low certainty).
1 finding from 1 review
Number of participants experiencing any serious adverse events · patients with osteoarthritis
1 finding from 1 review
Number of participants experiencing any serious adverse events · patients with osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
Number of participants experiencing any serious adverse events · Patients with osteoarthritis of the knee or hip
Tramadol alone may leads to higher number of participants experiencing any serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Proportion of participants experiencing adverse events · people with focal epilepsy
Losigamone showed no clear difference in the proportion of participants experiencing any adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · women with PMS
It is very uncertain whether oestrogen in combination with progestogen (sequential or continuous) changes withdrawal due to adverse events over 2 to 4 menstrual cycles1 compared with placebo (very low certainty).
1 finding from 1 review
Adverse drug withdrawal events ‐ relapse (endoscopic findings) · people with mild to moderate esophagitis, symptomatic, aged > 18 years (mean age 73 years)
It is very uncertain whether abrupt discontinuation deprescribing changes adverse drug withdrawal events ‐ relapse (endoscopic findings) compared with continued use (very low certainty).
1 finding from 1 review
Weight gain · patients with schizophrenia
1 finding from 1 review
Adverse events (AEs) (1 or more events) · patients with myocardial infarction
It is very uncertain whether lidocaine changes adverse events (AEs; adverse drug reaction): any adverse event compared with tocainide (very low certainty).
1 finding from 1 review
Adverse events (AEs; adverse drug reaction): sinus bradycardia · patients with acute myocardial infarction
It is very uncertain whether lidocaine changes adverse events (AEs; adverse drug reaction): sinus bradycardia compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Intervention not reported
Number of participants experiencing any serious adverse events · patients with osteoarthritis of the ankle
1 finding from 1 review
Adverse events: number of mild treatment‐related adverse events · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events at 4 weeks to 6 months Assessed by self‐report · people who smoke
Nicotine EC showed no clear difference in adverse events at 4 weeks to 6‐9 months Assessed by self‐report compared with NRT (moderate certainty).
1 finding from 1 review
Adverse events at 12 weeks to 6 months Assessed via self‐report · people who smoke
Nicotine EC may leads to higher adverse events at 12 weeks to 6 months Assessed via self‐report compared with behavioural support only/no support (low certainty).
1 finding from 1 review
Adverse events: infections (CTCAE grade ≥ 3) (longest available · people with newly diagnosed multiple myeloma ineligible for transplant
Summary of findings table ‐ Daratumumab plus standard therapy probably leads to higher adverse events: infections (CTCAE grade ≥ 3) (longest available compared with standard therapy (moderate certainty).
1 finding from 1 review
Adverse events: death ‐ at end of treatment (secondary outcome) · people with depression after stroke
1 finding from 1 review